Fall COVID and Flu Vaccine Guidance Is Stuck in Federal Limbo

Why Fall COVID and Flu Shot Guidance Has Stalled

Normally, by mid-August, federal health officials have settled the fall COVID-19 and influenza vaccine recommendations. This year that process is fractured. The FDA has done its part, issuing influenza vaccine composition guidance in March and COVID-19 vaccine guidance in May. But the CDC's Advisory Committee on Immunization Practices, known as ACIP, has not held its usual March or June meetings. That means the next step — turning the FDA decisions into practical recommendations for age groups, dosing, and immunocompromised patients — has not happened at the federal level.

The gap has not left clinicians without any direction. The Infectious Diseases Society of America, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians have all issued their own fall respiratory virus guidance. Insurers have also pledged to cover all recommended vaccines without cost-sharing through the end of 2027, according to legal counsel for the American Academy of Pediatrics.

At the same time, the FDA earlier this month approved the first mRNA influenza vaccine, Moderna's mFlusiva, for adults 50 and older. It remains unclear whether the product will be written into formal recommendations. A March federal court ruling halted efforts by Health and Human Services Secretary Robert F. Kennedy Jr. to reduce childhood vaccines and forced the CDC to restore earlier vaccination schedules. This week, President Trump issued an executive order that would cut the number of universally recommended childhood vaccines, split the measles, mumps, and rubella vaccine into separate components, and downgrade COVID-19 and flu shots for children to shared decision-making.

Medical organizations note that an executive order cannot change ACIP recommendations or CDC schedules, and many physicians are relying on guidance from before June 2025. The Vaccines for Children program is expected to remain unaffected, though HHS did not respond to requests for comment.

Who Is Filling the ACIP Void This Fall

The missing federal recommendation, not missing vaccines

The central issue is not supply. Fall respiratory vaccines are expected to be available. The missing piece is the formal ACIP recommendation that clinicians, pharmacies, and insurers typically use to standardize fall vaccination campaigns. Without that vote, the practical authority shifts to professional medical societies, which have stepped in with published guidance for routine and high-risk patients.

IDSA, AAP, ACOG, and AAFP become the de facto standard

The four major medical bodies have issued recommendations on fall COVID-19 and flu shots and related immunizations. Their guidance gives pediatricians, obstetricians, family physicians, and infectious disease specialists a workable reference point, but it does not carry the same legal weight as CDC schedules for school requirements or federal programs. In practice, physicians told MedPage Today they are using pre-June 2025 ACIP guidance, before the committee was reconstituted by Kennedy.

Moderna's mRNA flu shot is approved, not yet scheduled

The first mRNA influenza vaccine, mFlusiva, is cleared for adults 50 and older, but approval is not the same as a place on the fall schedule. Because ACIP has not met and federal guidance is in flux, Moderna's product enters the 2026-2027 season with an unresolved recommendation status, even as insurers have generally pledged cost-free coverage for recommended vaccines.

The executive order cannot rewrite the schedule on its own

The White House order attempts to shorten the universal childhood vaccine list, separate the MMR vaccine, and move COVID-19 and flu shots for children to shared decision-making. But medical groups and a prior federal court ruling make clear that such changes require lawful agency process, not an executive order. The court already forced the CDC back to earlier schedules, and the American Academy of Family Physicians says the order cannot change ACIP recommendations or CDC schedules.

The larger risk is falling vaccine confidence

Infectious disease experts warn that conflicting signals have a measurable consequence: confusion reduces uptake. David Freedman, MD, of the University of Alabama at Birmingham and the Infectious Diseases Society of America, said confusion leads to lower vaccination rates. Pediatric infectious disease specialist Flor Munoz, MD, of Baylor College of Medicine, said the real concern is that people may simply not come in for their shots.

What Patients, Clinicians, and Employers Should Do Now

The practical steps differ by group, but the common thread is that fall 2026 vaccination decisions are currently being guided by professional society recommendations rather than a new federal ACIP vote.

• For patients and families: Keep appointments for recommended COVID-19 and flu shots; insurers have pledged no-cost coverage through the end of 2027, including vaccines recommended by medical societies.
• For parents of children: Ask your pediatrician whether they are using pre-June 2025 ACIP guidance; the Vaccines for Children program should continue to provide vaccines for families who cannot afford them.
• For clinicians: Where federal guidance is absent, follow the fall respiratory virus recommendations issued by IDSA, AAP, ACOG, and AAFP, and document that your practice is relying on the pre-June 2025 schedule pending a lawful CDC change.
• For employers and pharmacies: Plan workplace and retail vaccination campaigns using current medical-society guidance; do not assume a new federal ACIP recommendation will be issued before the fall season, and confirm product coverage with insurers for the 2026-2027 plan year.
• For Moderna and competing manufacturers: Product access is not the same as recommendation status; the mFlusiva approval for adults 50 and older must still clear the guidance pathway, which remains unresolved this season.